Literature DB >> 2794558

Use of serum ultrafiltrate in the serum dilution test.

J E Leggett1, S A Wolz, W A Craig.   

Abstract

Although pooled human serum diluent is advocated in the serum dilution test, its use may compensate for protein binding defects in patients and yield nonrepresentative titers. To test this hypothesis, comparison was made of serum ultrafiltrate (molecular weight cutoff less than or equal to 30,000) serially diluted into either pooled serum ultrafiltrate or Mueller-Hinton broth with patient serum samples diluted into pooled human serum in 111 assays from 55 patients and 6 volunteers. Of 111 bactericidal titers in ultrafiltrate and/or Mueller-Hinton broth, 101 were within a single twofold dilution of titers in pooled human serum. Nine of 10 discordant titers involved highly bound drugs and were usually higher in ultrafiltrate than in pooled human serum. In seven additional volunteers with renal failure, titers in ultrafiltrate and in each volunteer's serum were higher than those diluted in pooled human serum (P = .002). Recommended methods using pooled serum diluent may not accurately predict actual bactericidal titers in patients with abnormal protein binding.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794558     DOI: 10.1093/infdis/160.4.616

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.

Authors:  D E Nix; J H Wilton; J Hyatt; J Thomas; L C Strenkoski-Nix; A Forrest; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

Authors:  L Aguilar; I P Balcabao; P Salvá; M Martín; J Costa; J Prieto; R Dal-ré
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Influence of assay methodology on the measurement of free serum ceftriaxone concentrations.

Authors:  S J Kohlhepp; D N Gilbert; J E Leggett
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.

Authors:  J M Hyatt; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 5.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.